Semaglutide for Obesity
(SELECT-LIFE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines the long-term effects of a medicine from a previous study on heart health. Participants will not receive any treatment; instead, they will complete a health survey every six months for up to 10 years. This will help researchers understand participants' health following the earlier study. It is suitable for those who participated in the initial heart health study and did not withdraw their consent. As an unphased trial, this study allows participants to contribute valuable insights into long-term heart health outcomes.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop your current medications. However, since the SELECT-LIFE study is survey-based and does not provide any treatment, you will likely continue your usual medications as prescribed by your doctor.
Why are researchers excited about this trial?
Unlike typical treatments for cardiovascular conditions, which often involve medications to manage symptoms and prevent further complications, the SELECT-LIFE study focuses on understanding the long-term effects of semaglutide in people who participated in the earlier SELECT trial. Researchers are excited about this follow-up study because semaglutide, primarily known as a diabetes medication that mimics a hormone called GLP-1 to lower blood sugar, may also have benefits for heart health. This trial aims to provide insights into how semaglutide might impact cardiovascular outcomes over the long term, potentially offering a new perspective on managing heart health beyond traditional treatments.
Who Is on the Research Team?
Clinical Transparency (dept. 2834)
Principal Investigator
Novo Nordisk A/S
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
SELECT Trial
Participants receive treatment as part of the SELECT trial
SELECT-LIFE Follow-up
Participants are monitored for long-term effects after the SELECT trial, including health questionnaires every 6 months
What Are the Treatments Tested in This Trial?
Interventions
- No treatment given
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novo Nordisk A/S
Lead Sponsor
Lars Fruergaard Jørgensen
Novo Nordisk A/S
Chief Executive Officer since 2017
MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark
Martin Holst Lange
Novo Nordisk A/S
Chief Medical Officer since 2021
MD from University of Copenhagen